Free Trial
NASDAQ:CHGA

Avalon GloboCare Q2 2026 Earnings Results & Report

Avalon GloboCare logo
$2.02 +0.01 (+0.50%)
As of 10/9/2026 04:00 PM Eastern

Avalon GloboCare reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$2.80.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Avalon GloboCare EPS Results

Actual EPS
-$2.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Avalon GloboCare Q2 2026 Earnings FAQ

Avalon GloboCare (NASDAQ:CHGA) reported earnings of -$2.80 per share for Q2 2026. The report was announced on Friday, August 14, 2026.

Avalon GloboCare Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:CHGA) is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey. Publicly available company materials have identified David Jin as a senior executive, although the company’s operating status, leadership and securities information may have changed. Avalon GloboCare has historically traded under the symbol AVCO; the symbol provided, CHGA, could not be independently confirmed as its current listing.

View Avalon GloboCare Profile